Precision BioSciences Announces Executive Leadership Change
DURHAM, N.C., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS®…
Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R B-cell Acute Lymphoblastic Leukemia (B-ALL)
Acceptable Toler ability and Safety Profile in 27 Patients with No Graft versus Host Disease (GvHD), No Grade ≥ 3 Cytokine Release Syndrome (CRS) , and No Grade ≥ 3 Neurotoxicity (ICANS) PBCAR0191…
Precision BioSciences to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
DURHAM, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS ®…
Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement
Research collaboration using ARCUS genome editing technology will initially include three gene targets, with right to select three additional gene targets; lead program focused on Duchenne Muscular…
Precision BioSciences Reports Third Quarter 2020 Financial Results and Provides Business Update
Expanded allogeneic CAR T development collaboration with Servier to include four new programs targeting hematological and solid tumors Advanced CAR T clinical pipeline, including a clinical…
Precision BioSciences to Report Third Quarter 2020 Financial Results on November 10, 2020
DURHAM, N.C., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS ®…
Precision BioSciences Announces U.S. Patent Trial and Appeal Board Upholds Allogeneic CAR T Patents
PTAB Rules in Favor of Precision BioSciences in Two Patent Interference Proceedings DURHAM, N.C., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage…
Precision BioSciences Appoints Alex Kelly as Chief Corporate Affairs Officer
DURHAM, N.C., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies…
Precision BioSciences to Present at Upcoming Virtual Investor Conferences in October
DURHAM, N.C., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies…
Elo Life Systems Appoints Food and Beverage Industry Technology Leader Alec Hayes as Vice President of Technology and Products
Durham, N.C., September 21, 2020 – Elo Life Systems, a food and agriculture company with a mission to improve human health and wellness, today announced that Alec Hayes, Ph.D., has joined Elo Life…
Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma
Increasing BCMA Surface Expression and Reduced Soluble BCMA Levels with Gamma Secretase Inhibitor Nirogacestat May Enhance Clinical Benefit in Combination with PBCAR269A, an Allogeneic BCMA-Targeted…
Precision BioSciences and Servier Expand CAR T Oncology Development Collaboration with Four New Programs Targeting Hematological and Solid Tumors
DURHAM, N.C. and PARIS, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology developing allogeneic CAR T and in vivo gene correction therapies…
